Background Persistent infection with high‐risk human papillomaviruses (hrHPV) types is
causally linked with the development of cervical precancer and cancer. HPV types 16 and …

Genital HPV infection is associated with development of cervical cancer, cervical neoplasia,
anogenital warts, and other anogenital cancers. A number of reviews have primarily …

Background A randomised double-blind placebo-controlled phase II study was done to
assess the efficacy of a prophylactic quadrivalent vaccine targeting the human …

The immune system uses innate and adaptive immunity to recognize and combat foreign
agents that invade the body, but these methods are sometimes ineffective against human …

Patients and clinicians experience the frustration of cutaneous viral warts caused by
infection with the human papilloma virus (HPV). Warts appear in various forms on different …

Abstract The American Cancer Society (ACS) has developed guidelines for the use of the
prophylactic human papillomavirus (HPV) vaccine for the prevention of cervical …

OBJECTIVE. Prophylactic vaccination of 16-to 23-year-old females with a quadrivalent
human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine has been shown to …

Human papillomavirus (HPV) causes cervical, vulvar, and vaginal cancers, precancerous
dysplasia, and genital warts. We report data for the longest efficacy evaluation to date of a …

Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young
women (1106) were randomized to receive one of three formulations of a quadrivalent HPV …

Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection
from HPV 6/11/16/18–related cervical, vaginal, and vulvar disease through 3 years. We …